> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Moves to Cement Complete Response Letter Transparency Policy
- URL: https://www.fdaweb.com/fda-moves-to-cement-complete-response-letter-transparency-policy/
- Published: 2026-07-07T12:00:00.000Z
- Updated: 2026-09-14T13:42:27.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5161413

FDA is preparing to formalize one of its most significant transparency initiatives in decades: the public release of Complete Response Letters (CRLs) issued to companies whose drug applications are rejected.

An agency-planned rulemaking [listed in the recent unified agenda](https://www.reginfo.gov/public/do/eAgendaViewRule?pubId=202510&RIN=0910-AJ16&ref=fdaweb.com) as “Proactive Disclosure of Complete Response Letters,” would amend FDA regulations governing the confidentiality and disclosure of regulatory correspondence and establish a formal framework for releasing redacted CRLs. It is scheduled for publication as a proposed rule in October.

FDA cited its authority under the Freedom of Information Act, Section 505(l) of the Federal Food, Drug, and Cosmetic Act, and existing information disclosure regulations. According to the agency, current regulations already provide substantial discretion to release information contained in CRLs and make clear that FDA's analyses and deliberations reflected in the letters are not the property of the application sponsor. The proposed rule would remove what FDA characterizes as the principal regulatory obstacle to broader disclosure — the assumption that the existence of a previously undisclosed application is itself confidential commercial information.

The move would transform what has largely been an FDA transparency initiative into a permanent regulatory policy, potentially reshaping how drug developers, investors, patients, and regulators understand unsuccessful marketing applications. Under the proposed rule, FDA would proactively publish CRLs while withholding information protected as trade secrets, confidential commercial information, or personal privacy information.

The agency’s push follows criticism that companies often provide limited descriptions of FDA rejection decisions, leaving investors, researchers, and patients without a complete understanding of why products fail to reach the market. [FDA officials have argued](https://fdaweb.com/login.php?sa=v&aid=D5159808&cate=&stid=%241%24G60.Xr0.%24YCLCen1TLTrR4x3HuduLO0&ref=fdaweb.com) that public disclosure is necessary because companies frequently characterize CRLs in broad terms, such as citing “additional information requests” or “manufacturing issues,” without fully explaining the agency’s concerns.

By releasing the letters, FDA believes stakeholders will gain greater insight into regulatory decision-making, including the agency’s expectations regarding clinical evidence, manufacturing controls, safety issues, and statistical analyses. The initiative also reflects broader efforts by FDA leadership to increase transparency around drug reviews and enforcement activities.

The pharmaceutical industry is expected to challenge several aspects of the policy, particularly the potential disclosure of commercially sensitive information. Drug developers argue that CRLs often contain detailed discussions of:

- clinical trial design and results;
- chemistry, manufacturing, and controls issues;
- regulatory strategies;
- deficiencies identified during review; and
- potential paths toward approval.

The proposed rule may also trigger debate over FDA’s authority to alter decades of disclosure practices. Critics argue that moving from confidential correspondence to proactive disclosure represents a major policy change that should receive careful legal review.

Industry attorneys have questioned whether FDA has sufficiently broad authority to release information associated with unsuccessful applications before a product reaches the market. A final rule could face legal challenges over whether FDA properly interpreted confidentiality requirements and whether the agency followed appropriate administrative procedures.

Meanwhile, a [recent petition](https://www.fdaweb.com/redact-crls-for-unapproved-applications-petition/) submitted by Covington & Burling on behalf of an unidentified major pharmaceutical company called on the agency to immediately establish a formal process for redacting confidential commercial information and trade secrets before releasing CRLs for unapproved drug and biologic applications.

Covington argued that FDA’s new approach exposes highly sensitive information, including detailed clinical deficiencies and FDA recommendations, which competitors could use to shortcut their own development programs. The petition also provided instances where recently released CRLs revealed FDA’s concerns about study design and statistical methodology, information not previously disclosed by sponsors.